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Abstract: The impact of vitamin D on sensory function, including pain processing, has been
receiving increasing attention. Indeed, vitamin D deficiency is associated with various
chronic pain conditions, and several lines of evidence indicate that vitamin D
supplementation may trigger pain relief. However, the underlying mechanisms of action
remain poorly understood. We used inflammatory and non-inflammatory rat models of
chronic pain to evaluate the benefits of vitamin D3 (cholecalciferol) on pain symptoms.
We found that cholecalciferol supplementation improved mechanical nociceptive
thresholds in monoarthritic animals and reduced mechanical hyperalgesia and cold
allodynia in a model of mononeuropathy. Transcriptomic analysis of cerebrum, dorsal
root ganglia and spinal cord tissues indicate that cholecalciferol supplementation
induces a massive gene dysregulation which, in the cerebrum, is associated with
opioid signaling (23 genes), nociception (14), and allodynia (8), and, in the dorsal root
ganglia, with axonal guidance (37 genes), and nociception (17). Among the identified
cerebral dysregulated nociception-, allodynia- and opioid-associated genes, 21 can be
associated with vitamin D metabolism. However, it appears that their expression is
modulated by intermediate regulators such as diverse protein kinases and not, as
expected, by the vitamin D receptor. Overall, several genes – Oxt, Pdyn, Penk, Pomc,
Pth, Tac1, Tgfb1 – encoding for peptides/hormones stand out as top candidates to
explain the therapeutic benefit of vitamin D3 supplementation. Further studies are now
warranted to detail the precise mechanisms of action but also the most favourable
doses and time windows for pain relief.
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Dear Editor, 
We hope this message finds you well and we thank you very much for your recent 
email. We are writing to you on behalf of all authors, with a special request for you to 
consider a revised version of our manuscript entitled “Cholecalciferol (vitamin D3) reduces 
rat neuropathic pain by modulating opioid signaling” by Poisbeau et al. for your consideration 
for publication as an article in Molecular Neurobiology.  
We would like to thank the editor and reviewers for their comments and suggestions. 
We have been able to address all the raised concerns. Considering the requested changes, 
which were not experimental in nature, we are confident that we have addressed all the 
remaining concerns related to the main text. We thus hope that you will find the revised 
version of our manuscript suitable for publication in Molecular Neurobiology. 
Yours sincerely, 
 
Pierrick Poisbeau  
 
 
Cover Letter Click here to access/download;Cover Letter;Letter to editor _
rev.docx
Point-by-point response to the referees 
Reviewer 1 
1. Please introduce (and consistently use) the nomenclature of vitamin D3 and its metabolite. 
Please do not confuse the reader by using two names for the same molecule. Moreover, please 
always write "vitamin D3" when you mean this molecule and not only "vitamin D", which 
some readers may interpret as "1,25(OH)2D3". 
Response: We thank the reviewer for pointing out some potential misunderstandings, due to 
imprecise naming, and an insufficiently detailed biochemical pathway of vitamin D. When 
needed, the appropriate names for vitamin D and its metabolites were inserted in the 
manuscript. In addition, we wrote a new section in the introduction chapter that now reads:   
“Vitamin D is now recognized as an active and pleiotropic neurosteroid in the brain, where it 
acts as a hormone and a paracrine/autocrine agent [1; 2]. In mammals, vitamin D synthesis 
begins with cleavage of the B ring of 7-dehydrocholesterol, in the epidermis, under UVB 
radiation (290-315 nm) producing an extremely unstable pre-vitamin D [3]. After 
spontaneous isomerization, this creates the precursor molecule, cholecalciferol, also 
commonly called vitamin D3, which is subjected to three further hydroxylations, two of which 
render it bioactive, the third one allowing for inactivation. The first hydroxylation step occurs 
under the activity of a number of microsomal cytochrome P450 enzymes. CYP27A1, CYP2J2 
and CYP3A4 are potential players for the addition of a hydroxyl group on C25 of vitamin D, 
but CYP2R1 appears to be the most implicated enzyme in the conversion of cholecalciferol 
into 25 hydroxyvitamin D3 (25OHD3), or calcidiol (Cheng et al., 2003; Schuster, 2011). 
25(OH)D is subsequently converted to 1,25 dihydroxyvitamin D (1,25(OH)2D) or calcitriol, 
by another cytochrome P450 enzyme, CYP27B1 also referred to as 1α-hydroxylase. Once 
metabolized, 1,25(OH)D promptly upregulates the expression of a third cytochrome P450, 
CYP24A1, which catabolizes both 25(OH)D and 1,25OHD into biologically inactive, water 
soluble calcitroic acid (Holick, 2007). Within the whole body, calcitriol binds to the vitamin 
D receptor (VDR) and induces the transcription of hundreds of genes.” 
 
2. A membrane receptor for vitamin D has not been formally characterized. Therefore, please 
do not confuse the reader about it and explain the observed effects via the only accepted 
vitamin D receptor, the nuclear receptor VDR. 
Response: Nearly 50 peer-reviewed published articles describe the interactions between 
calcitriol and PDIA3 receptor. We also demonstrated that, when compared to VDR, PDIA3 
transcripts are abundantly expressed in brain cells (Landel et al, 2018). However, in order to 
“not confuse the reader”, we exclusively focused our introduction on VDR. The section 
mentioning the membrane receptor for vitamin D was erased. 
 
3. Oral vitamin D3 supplementation of 7,500 IU/kg is extreme, this would translate to some 
500,000 IU for humans. Are no effects observed at more moderate doses that reflect human 
supplementation habits? Also 3500 IU/kg by gavage is still out of range. 
Response: We are sorry for possibly leading the reader on a wrong interpretation of our 
vitamin D3 supplementation. Each kilo of manufactured chow contained either 0 or 1,000 IU 
or 7,500 IU of vitamin D3. If we consider that a rat eats approximately 20 g of diet, every day, 
Response to Reviewer Comments
it means that the daily ingested dose of cholecalciferol is 0 or 20 IU or 150 IU. In a previous 
study, these kinds of doses were administered, for 3 months, to rats with a spinal cord injury 
and no adverse effect was observed (Gueye et al, 2015). However, to avoid any further 
confusion, we added a sentence in the Materials and Methods section which now reads: 
“Vitamin D3 (cholecalciferol) was provided in the diet (monoarthritic model) or by gavage 
(monoarthritic and neuropathic models). Animals were fed with either a control diet (1,000 
IU/kg), a vitamin D3-deficient diet (0 IU/kg) or a vitamin D3-supplemented diet (7,500 IU/kg) 
(INRA, France). If we consider that 300-350 g rats eat approximately 20 grams of chow, the 
administered doses of vitamin D3 were 60 IU/kg/day, 0 IU/kg/day and 450 IU/kg/day, 
respectively. Six weeks were required to reach the vitamin D-deficiency status. In parallel, a 
group of rats was vitamin D-supplemented by a weekly gavage (50,000 IU/ml, 200 µl/week) 
(Uvedose, Crinex). Control animals received the same volume of triglycerides, the diluent for 
vitamin D3. Supplementation, through diet or gavage, was performed during 4 weeks.” 
 
 4. It is unclear why in the year 2018 still microarrays are use and not RNA-seq. The 
advantages of the latter are obvious. Moreover, a link to the raw-data is missing. In addition, a 
meta-table with all microarray data would be essential, in order to follow the analysis 
procedure. 
Response: As mentioned in our initial manuscript (section M&M), all microarray data are 
available on the following website: ArrayExpress database (accession number E-MTAB-
6801). 
We agree with the referee that the RNA-seq technique should be favored. However, when our 
study was performed, cDNA microarray technique was still recommended. In addition, we 
would like to mention that we recently performed a comparative study – microarray versus 
RNA-seq – on the same cell types. To our delight, the final results were strongly similar.   
 
5. Ingenuity Pathway Analysis is outdated and replaced by more recent methods, please check 
"Enrichr". 
Response: We are surprised to learn that IPA is outdated when so many published papers 
report its use for analysing -omics data. However, as recommended by the reviewer, we 
subjected our transcriptomic data to Enrichr. Undoubtedly, this software provides interesting 
information but failed to highlight nociception and allodynia pathways. As a result, we 
considered that the IPA-associated analysis should remain in the article. 
 
6. The reference list is in part biased. It does not fully represent the modern state of the field 
and general findings in the filed of vitamin D are not mentioned while in part outdated older 
references are cited. 
Response: We thank the reviewer for asking us to update our references. After checking all 
recent publications on vitamin D, inflammation, pain and nerve growth, we added x 
publications: 
 Sassi et al, 2018 
 Bivona et al, 2018 
 Banafshe et al, 2018 
 Yong et al, 2017 
 de Oliveira et al, 2017 
 Helde-Frankling and Björkhem-Bergman, 2017 
We would be delighted if the reviewer can tell us whether other publications are missing. 
 
Minor comments: 
1. Was there really 300 µg (= 0.3 mg) RNA used for cDNA synthesis? This sounds far too 
much. 
Response: We thank the reviewer for pointing out this mistake. The mass was 0.3 micrograms 
(and not 0.3 mg). It now appears in the text as 300 ng. 
 
2. Please introduce every abbreviation at its first time use and apply it then consistently. This 
applies also to the Abstract, Figures and Tables. 
Response: We have thoroughly checked our manuscript and figures/tables for abbreviations 
and have added the appropriate introduction for all abbreviations used.  
 
3. Please double-check for the most-recent gene abbreviation nomenclature. Some gene 
names seem not to be correct or truncated. 
Response: We thank the reviewer for pointing out our out-of-date gene nomenclature. We 
have checked gene abbreviation on the genecards.org website and have added under 
parenthesis the most recent nomenclature to clarify our text. This applies to Ac5 (Adcy5), Jnk 
(Mapk8), Erk1 (Mapk3), Erk2 (Mapk1) and P38mapk (Mapk14). We have decided to keep 
both nomenclatures in order to stay in accordance with the multiple figures of pathways we 
have generated.  
 
Reviewer #2: This is a valuable study. It will be of interest to the readers of Molecular 
Neurobiology. 
Check thoroughly for grammatical errors; and image and figure legend legibility. 
Response: We thank the reviewer for his/her positive comment. As recommended, we 
thoroughly checked the manuscript for grammatical errors, and increased the neatness of our 
images and the font of our legends. 
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Abstract  
The impact of vitamin D on sensory function, including pain processing, has been receiving increasing 
attention. Indeed, vitamin D deficiency is associated with various chronic pain conditions, and several 
lines of evidence indicate that vitamin D supplementation may trigger pain relief. However, the 
underlying mechanisms of action remain poorly understood. We used inflammatory and non-
inflammatory rat models of chronic pain to evaluate the benefits of vitamin D3 (cholecalciferol) on 
pain symptoms. We found that cholecalciferol supplementation improved mechanical nociceptive 
thresholds in monoarthritic animals and reduced mechanical hyperalgesia and cold allodynia in a 
model of mononeuropathy. Transcriptomic analysis of cerebrum, dorsal root ganglia and spinal cord 
tissues indicate that cholecalciferol supplementation induces a massive gene dysregulation which, in 
the cerebrum, is associated with opioid signaling (23 genes), nociception (14), and allodynia (8), and, 
in the dorsal root ganglia, with axonal guidance (37 genes), and nociception (17). Among the identified 
cerebral dysregulated nociception-, allodynia- and opioid-associated genes, 21 can be associated with 
vitamin D metabolism. However, it appears that their expression is modulated by intermediate 
regulators such as diverse protein kinases and not, as expected, by the vitamin D receptor. Overall, 
several genes – Oxt, Pdyn, Penk, Pomc, Pth, Tac1, Tgfb1 – encoding for peptides/hormones stand out 
as top candidates to explain the therapeutic benefit of vitamin D3 supplementation. Further studies are 
now warranted to detail the precise mechanisms of action but also the most favourable doses and time 
windows for pain relief. 
 
 
Keywords 
Cholecalciferol; Analgesia; Steroid; Sciatic nerve constriction; Gene regulation; Opioid 
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Introduction 
Vitamin D is now recognized as an active and pleiotropic neurosteroid in the brain, where it acts as a 
hormone and a paracrine/autocrine agent [1; 2]. In mammals, vitamin D synthesis begins with cleavage 
of the B ring of 7-dehydrocholesterol, in the epidermis, under UVB radiation (ultraviolet B; 290-315 
nm) producing an extremely unstable pre-vitamin D [3]. After spontaneous isomerization, this creates 
the precursor molecule, cholecalciferol, also commonly called vitamin D3, which is subjected to three 
further hydroxylations, two of which render it bioactive, the third one allowing for inactivation. The 
first hydroxylation step occurs under the activity of a number of microsomal cytochrome P450 
enzymes. CYP27A1, CYP2J2 and CYP3A4 are potential players for the addition of a hydroxyl group 
on the C25 of vitamin D, but CYP2R1 appears to be the most implicated enzyme in the conversion of 
cholecalciferol into 25-hydroxyvitamin D3 [25(OH)D3], or calcidiol (Cheng et al., 2003; Schuster, 
2011). 25(OH)D is subsequently converted to 1,25-dihydroxyvitamin D [1,25(OH)2D] or calcitriol, by 
another cytochrome P450 enzyme, CYP27B1 also referred to as 1α-hydroxylase. Once metabolized, 
1,25(OH)2D promptly upregulates the expression of a third cytochrome P450, CYP24A1, which 
catabolizes both 25(OH)D and 1,25(OH)2D into biologically inactive, water soluble calcitroic acid 
(Holick, 2007). Within the whole body, calcitriol binds to the vitamin D receptor (VDR) and induces 
the transcription of hundreds of genes. 
Evidence linking vitamin D and pain is based on in vitro, animal, epidemiological and clinical 
research. For instance, four observational studies report that hypovitaminosis D is associated with 
various forms of chronic pain [4-7]. Rats fed during 2-4 weeks with a vitamin D-deficient diet 
displayed mechanical deep muscle hypersensitivity [8]. Pain relief was also observed in vitamin D-
treated patients with fibromyalgia syndrome [9] or musculoskeletal complaints [10]. 
Although the published clinical studies are heterogeneous and sometimes of poor methodological 
quality, three meta-analyses of randomized, placebo-controlled trials were conducted [11-13]. They all 
conclude that there is modest level of evidence that vitamin D supplementation is efficient to treat 
chronic pain. In line, reviews of published randomized controlled trials report that vitamin D induces a 
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significantly greater mean decrease in pain score for patients with chronic pain, compared with 
placebo [14-16], especially when patients display calcidiol [25(OH)D] levels below 30 nmol/L [17]. 
The basis for considering vitamin D as a potential pain killer stems partially from its well established 
role as a modulator of inflammatory and immune responses [18; 19]. In human lung fibroblasts, 
cholecalciferol, calcidiol and calcitriol inhibit the production of prostaglandin E2 (PGE2), a key factor 
in inflammatory pain [20], and its level of expression is reduced in patients with musculoskeletal pain 
treated with high doses of vitamin D3 [21]. However, since vitamin D supplementation could also be 
efficient in reducing symptoms in non-inflammatory chronic pain, other mechanisms may be at play 
[22]. 
Administration of vitamin D3 attenuated cold allodynia and heat hyperalgesia in a rat model of 
neuropathic pain, when delivery was started on the first day after surgery [23]. We also demonstrated 
that vitamin D3 supplementation improved functional recovery and myelination [24; 25]. 
Subsequently, we noticed a cholecalciferol-associated diminution of pain in humans with arm and/or 
hand nerve trauma (unpublished data). In order to assess whether cholecalciferol is a true pain-
modulator and identify its potential mechanisms of action, we performed the current study, based on 
two rat models of pain - knee monoarthritis and mononeuropathy - that represent good examples of 
chronic pain associated with various degrees of inflammation. Animals were supplemented with 
cholecalciferol for several weeks after which their nociceptive sensitivity to mechanical and cold 
stimuli was quantified. At the end of the experiment, the cerebrum, dorsal root ganglia (DRG) and 
spinal cord were collected and analyzed, by means of cDNA microarrays, quantitative PCR and 
bioinformatic tools, in order to identify the vitamin D-associated genes involved in nociception. 
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Methods 
 
Animals and pain models 
Male Sprague Dawley rats weighing 250-350 g (Janvier Le Genest St. Isle, France) were housed in 
groups of three, under standard conditions (room temperature: 22°C; 12/12h light-dark cycle) with ad 
libitum access to food and water. All experiments were conducted in conformity with the 
recommendations of the European Committee Council Direction of September 22, 2010 (2010/63/EU). 
Procedures were positively evaluated by the regional ethical committee and experiments were 
conducted with an official authorization for animal experimentation from the French Department of 
Agriculture (License 67-116 to PP).  
Knee monoarthritis: Transient inflammation of the rat knee was induced by unilateral injection of 
50 µL CFA [complete Freund’s adjuvant (Sigma St Louis, MO, USA)] under light isoflurane 
anesthesia (3%), as previously published [26]. Control animals received a similar volume of mineral 
oil, the diluent for CFA (Sigma Aldrich, St Louis, USA). 
Mononeuropathy: To produce a controlled constriction of the sciatic nerve, we used the cuff model 
which has been well characterized previously in our laboratory [27].  The surgical procedure was 
carried out under aseptic conditions and ketamine/xylazine anesthesia (ketamine 87mg/mL, xylazine 
13 mg/mL, i.p. (intra-peritoneal) 10 mL/kg; Centravet, Taden, France). The common branch of the 
right sciatic nerve was exposed and a 2 mm long split section of polyethylene tubing (ID = 0.86 mm, 
ED = 1.27 mm; PE-90, Harvard Apparatus, Les Ulis, France) was placed around it (Cuff group). The 
shaved skin layer was then closed using suture. Sham-operated rats underwent the same surgical 
procedure as described above but without implantation of the cuff (Sham group).  
 
Nociceptive tests 
Mechanical nociceptive threshold: Mechanical nociceptive thresholds were measured using a 
calibrated forceps (Bioseb, Vitrolles, France), as previously described [28]. All animals were 
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habituated to the room and the tests, at least one week before the initial experiments. Habituated rats 
were loosely restrained, with a towel masking the eyes, in order to limit the stress induced by 
environmental stimulations. The tips of the forceps were placed on each side of the paw and a 
gradually increasing force was applied. The pressure, in gram, producing withdrawal of the paw or, in 
some rare cases, vocalization of the animal, was considered as the nociceptive threshold value. This 
manipulation was performed three times for each hindpaw and values were averaged. All tests were 
performed between 10:00 AM and 4:00 PM, prior to drug treatment. 
Cold allodynia: Thermal cold allodynia was assessed by scoring the aversive behaviors of rats using 
the acetone test, as previously published [29]. Rats were placed on a wire mesh delimited by a 
PlexiglasTM cage and allowed to accommodate for at least 15 min. A drop of acetone was then placed 
on the ventral side of the hindpaw, producing a non-noxious decrease in temperature during 
evaporation. The rat behavioral response was scored during 20 s following acetone application as 
follows: 0, no response of the animal; 1, quick withdrawal, flick or stamp of the paw; 2, prolonged 
withdrawal or repeated flicking of the paw; and 3, repeated flicking of the paw with licking of the paw. 
Manipulation was performed three times for each paw and values were added (maximal score: 9). 
 
Drugs and treatments 
Vitamin D3 (cholecalciferol) was provided in the diet (monoarthritic model) or by gavage 
(monoarthritic and neuropathic models). Animals were fed with either a control diet (1,000 IU/kg), a 
vitamin D3-deficient diet (0 IU/kg) or a vitamin D3-supplemented diet (7,500 IU/kg) (INRA, France). 
If we consider that 300-350 g rats eat approximately 20 grams of chow, the administered doses of 
vitamin D3 were 60 IU/kg/day, 0 IU/kg/day and 450 IU/kg/day, respectively. Six weeks were required 
to reach the vitamin D-deficiency status. In parallel, a group of rats was vitamin D3-supplemented by a 
weekly gavage (50,000 IU/mL, 200 µL/week) (Uvedose, Crinex). Control animals received the same 
volume of triglycerides, the diluent for vitamin D3. Supplementation, through diet or gavage, was 
performed during 4 weeks.  
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ADVIA Centaur® Vitamin D total analysis 
This assay is a one-step, automated direct competitive chemiluminescent immunoassay that detects 25-
OH vitamins D2 and D3 in serum. It employs a proprietary releasing reagent, an anti-fluorescein 
monoclonal mouse antibody covalently bound to paramagnetic particles, an anti-25(OH)D monoclonal 
mouse antibody labeled with acridinium ester, and a vitamin D analog labeled with fluorescein. There 
was an inverse relationship between the resulting chemiluminescent signal detected by the system and 
the amount of vitamin D present in the sample. This assay is standardized against LC-MS/MS (liquid 
chromatography coupled to tandem mass spectrometry). The assay range is 9.3 nmol/L to 375 nmol/L. 
 
Microarray assay 
Lower lumbar DRG, lumbar spinal cord and cerebrum were collected from all groups. Rats were 
anesthetized with isoflurane before sacrifice and tissues isolated from each animal, before being snap-
frozen in liquid nitrogen and stored at -80°C until use. Total RNA was isolated from the snap-frozen 
tissues using RNeasy Mini kit (Qiagen, Courtaboeuf, France), according to the manufacturer’s 
instructions. RNA concentration was determined using a Nanodrop 2000 spectrophotometer (Life 
Technologies ThermoFisher Scientific, Villebon sur Yvette, France) and RNA integrity assessed on an 
Agilent 2100 Bioanalyzer (Agilent Technologies, Les Ulis, France). 
RNA samples from 3 animals in each group were pooled for microarray hybridization. Unwanted 
genomic DNA was removed using a DNase set kit (#79254, Qiagen). Purified total RNAs were 
processed for hybridization on genome-wide DNA microarrays within one month. Cyanine-3-labeled 
cDNA was generated from 300 ng of RNA using the One-Color Low RNA Input Linear Amplification 
kit (Agilent Technologies) according to the manufacturer’s instructions, followed by purification on a 
RNeasy column (Qiagen). All amplified cDNAs were checked for dye incorporation, cDNA yield and 
amplification profile. Only those fitting all quality criteria were fragmented for further hybridization 
onto microarrays. Samples were then carefully hybridized onto Agilent Whole Rat Genome (4644K) 
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Oligo Microarrays (G4131F). Microarrays were scanned using an Agilent DNA microarray scanner 
G2505B. Data are available on the ArrayExpress database (accession number E-MTAB-6801).  
 
Microarray data analysis  
Individual microarray quality was evaluated based on quality control report, pair-wise MA-plots (with 
M the log ration and A the mean average), and box plots. Intra-array normalization of raw signals from 
the 8 microarrays (corresponding to the four above-mentioned conditions in duplicates) was performed 
using Feature Extraction software 9.1.3.1 (Agilent Technologies®). Microarray normalized data were 
further exported into the Limma package, for inter-array normalization using the quantile method. 
Statistical analysis was performed using the TIGR MeV (MultiExperiment Viewer) v4.4 software 
(http://www.tm4.org/mev.html) and the GeneANOVA program. The multi-way ANOVA (analysis of 
variance) model was implemented: first, to identify differentially regulated genes when accounting for 
the multiple sources of variation in the microarray experiment; second, to evaluate the effect of the 
main variable, i.e. the addition of cholecalciferol. Multiple test correction was further carried out using 
the false discovery rate method. Cluster and Tree View softwares were used for unsupervised 
hierarchical clustering. 
Biological interpretation of the data was performed using Ingenuity Pathway Analysis (IPA, Ingenuity 
Systems). The main criterion to validate a differentially expressed gene was a fold change over 1.5 or 
under -1.5 when considering expression values in the group supplemented with vitamin D3 relative to 
the control diet group, whether considering control or experimental animals. Upregulated and 
downregulated genes were analyzed in the same data sets to obtain the biologically relevant function 
categories. Right-tailed Fisher’s exact test was used to calculate a p-value determining the top 
statistically significant biological functions assigned to the data set.  
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Real-time quantitative PCR (RT-qPCR) 
Tissue from cerebrum and lower lumbar DRG of all animal groups were collected, reconstituted in a 
guanidine thiocyanate/β-mercaptoethanol preparation using ultraturax and stored at -80°C. Total RNA 
was extracted according to a protocol derived from the original procedure of Chomczynski and Sacchi 
[30], consisting of two independent total RNA extractions separated by a DNAseI treatment (TURBO 
DNaseTM, Ambion, Life technologies, Saint Aubin, France), as previously described in detail [31]. 
800ng RNA were used for reverse transcription with the RT iScript kit (Bio-Rad, Marnes-la-Coquette, 
France). RT-qPCR was performed using SYBR Green Supermix (Bio-Rad), on the iQ5 Real Time 
PCR System (Bio-Rad). Amplifications were carried out in 42 cycles (20 s at 95°C, 20 s at 60°C and 
20 s at 72°C). Serial dilutions of samples were used to create standard curves, after which relative gene 
expression was calculated as the ratio between cDNA concentration of the gene of interest and that of 
the housekeeping gene. To specifically amplify mRNA encoding various rat proteins, we designed all 
our specific primer sets (sense and antisense respectively) to get an optimal annealing efficacy at 60°C 
using Oligo6.0 and M-fold software for selected genes. Primer sequences and their spanning regions in 
NCBI sequences are given in supplementary table 1. 
To standardize the experiments, four classic housekeeping genes were tested; i.e beta2-microglobulin 
(B2m), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-glucuronidase and hypoxanthine 
guanine phosphoribosyl transferase (HPRT). Preliminary experiments showed that HPRT transcripts 
were very stable between samples. Therefore, HPRT was selected as the housekeeping gene. Samples 
were accurately dispensed in duplicates using a robotic workstation (Freedom EVO100, Tecan, Lyon, 
France), and amplification efficacy given by standard curves was always close to 100% (± 2%), whilst 
amplification specificity was assessed by a melting curve study. 
 
Statistics 
All data are expressed as mean ± standard error of the mean (SEM). Two-way repeated-measures 
analysis of variance (RM tw ANOVA), followed by Bonferroni posthoc tests were used to analyze the 
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effects on mechanical/thermal nociception. RT-qPCR results were analyzed with one-way ANOVA 
followed by Sidak’s posthoc test. Differences were considered statistically significant for p < 0.05. 
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Results 
 
Vitamin D3 supplementation reduces mechanical hyperalgesia in monoarthritic rats 
The modulatory action of vitamin D3 on pain symptoms was first evaluated using a model of transient 
inflammatory pain induced by a single intra-articular injection of CFA. This classical model of knee 
monoarthritis rapidly induces a local inflammation associated with mechanical hyperalgesia of the 
ipsilateral hindpaw (Figure 1a). Compared to control values (just before injection at t = 0 : 
295.8 ± 2.4 g), mean mechanical nociceptive thresholds dropped significantly to a minimal value of 
168.1 ± 5.9 g, 24 hours after CFA injection (n = 6) in control animals receiving normal food. Mean 
mechanical nociceptive threshold remained unchanged for the ipsilateral hindpaw of rats injected with 
the vehicle of CFA (Figure 1b) and for all contralateral hindpaws (data not shown). When present, 
mechanical hyperalgesia persisted for about 3 weeks since mechanical nociceptive thresholds returned 
to control values 21 days after CFA injection.  
Plasma concentrations of the active metabolite of calcitriol (1,25-dihydroxyvitamin D) were 
48.94 ± 3.42 ng/mL (n = 11) for rats under normal diet and around 120 ng/mL for rats supplemented 
for 4 weeks (food: 119.93 ± 6.25 ng/mL, n = 6; gavage: 135.20 ± 9.14 ng/mL, n = 5). Data were 
statistically different from normal food rat group at p < 0.001 with the Kruskal-Wallis test 
(KW = 16.10) followed by Dunn's posthoc test (normal food vs food supplementation: p < 0.01; 
normal food vs normal food+gavage: p < 0.001). 
 
Figure 1 near here 
After 4 weeks of supplementation with vitamin D3 in their food or by weekly gavage, we found that 
rat mechanical hyperalgesia was significantly reduced compared to those under normal diet (RM tw 
ANOVA, time x treatment, F(15, 75) = 5.59, p < 0.001). 24 hours after CFA injection, thresholds reached 
a minimal value of 215.6 ± 6.9 g and of 222.4 ± 10.7 g for rats receiving vitamin D3 food 
supplementation (n = 6) and gavage (n = 6), respectively. Normalized to the mean threshold observed 
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in rats under normal diet, these values corresponded to a 30-40 % reduction in hyperalgesia. 
Accordingly, at the end of week 2, no sign of hyperalgesia was observed in supplemented animals 
whereas rats from the other groups still displayed significantly lower mean mechanical nociceptive 
thresholds compared to baseline. No difference in the time course of pain symptoms was observed 
between the two groups of unsupplemented and vitamin D3-deficient rats (Figure 1a).  
 
Vitamin D limits neuropathic pain symptoms and accelerates recovery 
We then investigated the consequences of vitamin D3 supplementation, using rat gavage for 4 weeks, 
on a neuropathic pain model induced by a chronic constriction of the sciatic nerve. This well-
characterized model of neuropathic pain is associated with long-lasting mechanical hyperalgesia and 
cold allodynia (Figure 2). After the cuff surgery, mechanical hyperalgesia developed as indicated by a 
decrease in the mean mechanical nociceptive threshold (Figure 2a1). Thresholds were significantly 
different between the cuff- and sham-operated groups (Figure 2a1: RM tw ANOVA, time x surgery, 
F(5,25) = 11.25, p < 0.001; n = 6 rats per group). In respect with cold allodynia measured with the 
acetone test, differences between sham and cuff groups were also observed (Figure 2a2: RM tw 
ANOVA, time x surgery, F(5,25) = 29.88, p < 0.001; n = 6 rats per group).  
Figure 2 near here 
Similarly to the monoarthritic model, animals receiving vitamin D3 supplementation displayed 
significantly reduced mechanical hyperalgesia (RM tw ANOVA, time x treatment, F(5, 25) = 8.57, 
p < 0.001; n = 6 rats per group) and cold allodynia (RM tw ANOVA, time x treatment, F(5, 25) = 6.73, 
p < 0.001; n = 6 rats per group) when compared to the unsupplemented group. After one week, 
hyperalgesia-associated mechanical thresholds raised significantly (control food: 159.97 ± 8.44 g; 
control food + gavage: 215.11 ± 8.13 g; n = 6) while cold allodynia scores diminished significantly 
(control food: 6.00 ± 0.68 g; control food + gavage: 3.50 ± 0.56 g; n = 6). Overall, vitamin D3-
associated modulation of pain symptoms, after one week of treatment, was about 40.6 % and 45.5 %, 
respectively for mechanical and cold modalities. Mechanical sensitivities and behavioral scores in 
13 
 
 
 
response to acetone reached similar values to sham-operated control animals 3 weeks after surgery. No 
withdrawal (i.e. re-appearance of pain symptoms) was observed during the following days (data not 
shown). In this model, spontaneous recovery is observed after 60 to 90 days. Altogether, these data 
suggest that vitamin D3 supplementation accelerates the recovery of these animals as demonstrated by 
the rapid reduction in pain symptoms. 
Because neuropathic pain may appear after surgery in some clinical cases, we also evaluated the 
benefits of introducing an immediate postsurgical vitamin D3 treatment. Figure 2b illustrates the time 
course of mechanical nociceptive thresholds after cuff surgery. The new kinetic profile is very similar 
to the previous one. Mechanical allodynia was strongly and significantly reduced one week after 
surgery (RM tw ANOVA, time x treatment, F(5, 25) = 11.40, p < 0.001). Moreover, mechanical 
hypersensitivity fully disappeared 2-3 weeks after surgery in vitamin D3 treated rats whereas control 
rats still exhibited pain symptoms. It can thus be concluded that vitamin D3 limits pain symptoms in 
these two models and accelerates recovery from persistent pain states.  
 
Vitamin D3 induces a massive tissue-dependent gene dysregulation 
Since calcitriol exerts most of its biological effects by modulating gene transcription, we then 
performed transcriptomic experiments in order to investigate possible genomic pathways explaining its 
modulatory effect on pain symptoms. We analyzed three nervous tissues of interest: DRG, spinal cord 
and cerebrum. Supplementary table 2 lists the 1,285 genes that were dysregulated, in at least one of the 
three tissues, after 4 weeks of cholecalciferol supplementation in neuropathic animals. In the cerebrum, 
the number of under- (187) and over-expressed (145) genes was nearly even. In contrast, in the spinal 
cord (69 vs 200) and DRG (278 vs 482), dysregulated genes were predominantly over-expressed.  
Figure 3a reveals that vitamin D3 supplementation induced a dysregulation of more than twice as 
many genes in the DRG as compared to the cerebrum or the spinal cord. Interestingly, only three genes 
– Mrpl43 (Mitochondrial ribosomal protein L43), Myh7 (Myosin Heavy Chain 7) and Syn1 (Synapsin 
1) - were commonly dysregulated in the three nervous tissues, after vitamin D3 treatment. Mrpl43 was 
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under-expressed in all three tissues while Myh7 and Syn1 were under-expressed in the cerebrum but 
over-expressed in the spinal cord and DRG.  
Figure 3 near here 
Using the IPA software, the clustering of the area-specific dysregulated genes indicated that among the 
top canonical pathways, the ones displaying the highest significance were: the opioid signaling 
pathway (23 genes), dendritic cell maturation (12) and axonal guidance signaling (37), for the 
cerebrum, spinal cord and DRG, respectively (Figure 3b). Furthermore, integrin linked kinase (ILK) 
signaling, via its cytosolic kinase activity and/or modulatory role on nuclear gene expression, stands 
out as the prime common canonical pathway.  
 
Vitamin D3 modulates nociception and allodynia in a tissue-specific manner 
To unveil the detailed role of vitamin D3 in nociception and allodynia, we narrowed our analysis to the 
genes that are directly associated with these two functions. As summarized in Figure 3c, when 
comparing vitamin D3-supplemented with unsupplemented neuropathic rats, we observed 14 and 17 
nociception-associated genes which expression was dysregulated in the cerebrum and DRG, 
respectively. Within these two pools, only one gene – Cx3cl1 (C-X3-C Motif Chemokine Ligand 1) – 
was commonly dysregulated, although in an inverted way. In regard to allodynia, 8 and 5 genes were 
dysregulated in the cerebrum and spinal cord, respectively (Figure 3d), none of them being 
misexpressed in both tissues. Within the cerebrum, three genes that are involved in the modulation of 
nociception and allodynia – Pdyn, Penk and Pomc – encode major ligands of the opioid signaling 
pathway (prodynorphin, proenkephalin and proopiomelanocortin, respectively; Figure 4). No 
allodynia-associated dysregulated gene was observed in the DRG and no nociception-associated 
dysregulated gene was noticed in the spinal cord. The 23 genes associated with opioid signaling 
(Figure 4) are: Adcy5, Ap2b1, Ap2s1, Ctnnb1, Fos, Gnal, Gnas, Gng7, Gsk3b, Itpr1, Myc, Pde1b, 
Pdyn, Penk, Plcb1, Pomc, Ppp3ca, Prkcb, Prkcd, Rgs3, Rgs9, Sos1, Th.  
Figure 4 near here 
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At this point, we decided to validate the observed expression of several dysregulated genes of our data 
set, using RT-qPCR performed on samples extracted from animals having received sham or sciatic 
cuff surgery with or without vitamin D3 supplementation. We chose to sort out the data from both 
DRG and cerebrum tissues, using three major classes of genes. First, we focused on the opioid system 
(Figure 5) in cerebrum samples. We observed that pro-dynorphin and pro-enkephalin transcripts were 
up-regulated in injury conditions but returned to basal levels after vitamin D3 treatment. Conversely, 
the Pomc gene, known to give rise to many endogenous opioid peptides including met-enkephalin and 
β-endorphin, was overexpressed in cuff animals supplemented with vitamin D3. In addition, opioid 
receptors remained unaffected in our paradigm, promoting the hypothesis that the analgesic 
endogenous opioid pathways may actively participate in vitamin D actions. This activation appears 
quite selective since DRG samples extracted from the very same animals did not show a similar 
pattern.   
Figure 5 near here 
A second class of genes (Supplementary Figure 1) which raised our attention includes numerous 
neurotransmitters/neuropeptides and neurotrophic factors. Here we show that differential patterns of 
secreted molecules expressed in the DRG and cerebrum are modulated by nerve injury and vitamin D3 
supplementation. Indeed, cerebral Avp (vasopressin), Oxt (oxytocin), Adcyap1 (PACAP), Gal (galanin) 
and Hcrt (orexin) genes were significantly up-regulated by vitamin D3 in cuffed condition whilst other 
such as Tac1 (tachikinin) and Npy (neuropeptide Y), which expression is exacerbated by the lesion, 
returned to basal levels upon vitamin D administration. In the DRG, similar situations have been 
observed with Gdnf (glial cell derived neurotrophic factor), Ngf (nerve growth factor), Gdf10 (growth 
differenciation factor 10), Nrtn (neurturin) and Ngr1 (neuregulin 1) transcripts going up after vitamin 
D3 supplementation of injured animals and Nppb (encoding the precursor of the brain natriuretic 
peptide) gene expression enhanced in cuffed condition but restored by vitamin D3.   
Finally a last set of genes (Supplementary Figure 2), dealing with inflammation and extracellular 
matrix remodeling, was also scrutinized in our analysis. RT-qPCR confirmed that, in the cerebrum, 
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Cx3cl1 and Adam11 (metalloprotease) gene up-regulation observed in cuffed condition was abrogated 
by vitamin D3 treatment whilst Timp4 (a member of the metalloprotease inhibitor family) was solely 
up-regulated in vitamin D3-treated cuffed samples. In line with these findings, we also observed 
changes in Cxcl14 (C-X-C Motif Chemokine Ligand 14), Cx3cl1 and Ccl21b (C-C Motif Chemokine 
Ligand 21) chemokine transcript levels in DRG with Cxcl14 and Ccl21b up-regulated in cuffed 
condition and Cx3cl1 mRNA by vitamin D3 instead. A similar situation was observed for extracellular 
matrix remodeling with Mmp9 and Mmp16 (matrix metallopeptidases 9 and 16) expression enhanced 
by the lesion and Adamts12 (metalloprotease with thrombospondin) solely up-regulated after vitamin 
D3 treatment.  
 
Nociception and allodynia may be modulated by inactive and active forms of vitamin D 
To further decipher the modes of action of vitamin D and its metabolites, we used the IPA software to 
identify the intermediate regulators linking vitamin D3 to the misexpressed genes that, within the 
cerebrum, are associated with allodynia, nociception and opioid signaling. Our research was focused 
on calcitriol, the active form, but also on its two precursors: cholecalciferol and calcidiol. Figure 6 
indicates that cholecalciferol, calcidiol and calcitriol are associated with 9, 8 and 24 dysregulated 
genes, respectively. The three metabolites regulate a common pool of 5 genes: Ctnnb1, Fos, Myc, 
Pomc, Th.  
Figure 6 near here 
Each molecule acts in its own way. Cholecalciferol and calcidiol share a similar outcome but none of 
the intermediate regulators. Many genes associated with cholecalciferol are part of the pool of 
transcripts regulated by calcitriol (Figures 6a, c). Conversely, calcidiol stands out as the only molecule 
that is linked to a modified expression of Itpr1 (Inositol 1,4,5-Triphosphate Receptor Type 1; Figure 
6b). Calcitriol is associated to the highest number of transcripts of interest and operates through two 
levels of regulators (Figure 6c).  
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We next explored the tissue-specific mechanisms and compared the consequences of vitamin D3 
supplementation on gene expression. In the interest of simplification, we show here the metabolic 
pathways associated with cholecalciferol. Supplementary figure 3 reveals a similar profile with 5 
common signaling regulators – Erk1/2 (i.e. Mapk3/1), Jnk (i.e. Mapk8), P38Mapk (i.e. Mapk14), 
Prkca, Smad – for the three tissues. Nevertheless, the final result differs dramatically from one tissue 
to another. 
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Discussion 
Notwithstanding accumulating evidence indicating that hypovitaminosis D is a risk factor for various 
forms of pain, the current behavioral and transcriptomic study is, to our knowledge, the first one to 
assess the effects of a short-term cholecalciferol supplementation in the central (cerebrum and spinal 
cord) and peripheral (DRG) nervous systems of rats with chronic pain. We observed a dramatic 
improvement in nociceptive thresholds and allodynia scores as well as a massive and heterogeneous 
gene dysregulation in the three scrutinized tissues of mononeuropathic animals supplemented with 
vitamin D3. A large number of dysregulated genes is associated with (i) opioid signaling, nociception 
and allodynia, in the cerebrum, and (ii) axonal guidance and nociception, in the DRG. Reassuringly, 21 
identified cerebral dysregulated genes are associated with vitamin D metabolites and either nociception 
and/or allodynia and/or opioid signaling. We show here that the anti-nociceptive action of vitamin D3 
in the brain involves signaling through Erk1/2 (i.e. Mapk3/1), Map2k1/2, Pth, Src and not, as expected, 
Vdr.  
 
A confirmed immuno-modulatory role  
To assess the pain-alleviating effect of cholecalciferol, we first opted for a knee monoarthritis model, 
in which a transient inflammation is induced by a unilateral injection of CFA. Vitamin D being a 
potent immune modulator [32; 18; 19], an impact on inflammatory and immune processes can be 
expected. Indeed, it has been shown that calcitriol-treated T-cells produced more anti-inflammatory 
cytokines and less pro-inflammatory cytokines [33-37] for a recent review see [37]. However, 
unveiling the precise immune-modulatory modes of action of vitamin D was beyond the scope of this 
study. We chose instead to detail the molecular mechanisms underlying vitamin D3 anti-nociceptive 
effects in a supposedly non-inflammatory model, namely mononeuropathy. 
Claiming that this model is devoid of inflammation would be misleading, as it is associated with a 
moderate inflammation, highlighted by an altered expression of several inflammatory-related genes, 
which can be improved by vitamin D3 supplementation. For example, C1qa, C1qc, Il13ra1 and Irf2 
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(coding for Complement C1q A and C chains, Interleukin 13 receptor subunit alpha 1 and Interferon 
regulatory factor 2, respectively), over-expressed in unsupplemented animals, are down-regulated after 
cholecalciferol treatment. To a degree, this immuno-modulatory action may explain the reduced pain 
symptoms. 
 
A Pomc-related pain relief 
The modulation of opioid signaling by vitamin D3 is one of the major findings of our study. Among 
the 23 cerebral dysregulated genes that are part of this pathway, three – Pdyn, Penk, Pomc - are 
noticeable in the cerebrum since they code for endogenous opioids - prodynorphin, dynorphin, leu-
enkephalin, met-enkephalin, β-endorphin – that are involved in the sensory perception of pain [38]. An 
intriguing finding is the imbalanced expression of the P trio: Pomc (+5.4) is up-regulated while Pdyn (-
2.8) and Penk (-2.6) are down-regulated. Although a few studies indicate a differential modulation of 
these three transcripts [39; 40; 3], such a disparity is hard to comprehend. However, Pdyn, Penk, Pomc 
belong to the opioid/orphanin gene family but they are not (i) located on the same chromosome, (ii) 
expressed by identical brain areas or cell types nor (iii) regulated by the same molecules. For instance, 
Pdyn and Penk expression is potentially modulated by Adora2a (adenosine A2a receptor) and Drd2 
(dopamine receptor D2) [41] while Pomc is regulated by Avp [42]. Interestingly, the latter is over-
expressed in the cerebrum and the formers are under-expressed. Likewise, Fos, which modulates the 
expression of Pomc [43], is over-expressed whereas Ctnnb1, potential regulator of Pdyn, is under-
expressed. This differential regulation could explain the results obtained in this study. 
In addition to the altered expression of three opioid agonists, not associated with a modified 
transcription of opioid receptors, our study reveals a substantial dysregulation of G proteins subunits 
and second messengers. When delivered acutely, opioid agonists inhibit adenylyl cyclase (AC) activity 
[44], as observed here for Adcy5. Conversely, a chronic opioid treatment increases AC levels, inducing 
a superactivation of cAMP which leads to opioid tolerance and dependence [45]. After binding of the 
agonists, opioid receptors go through a phosphorylation process triggered by G protein-coupled 
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receptor kinases (GRK) and second messenger-regulated kinases (PKC, PKA, CaMK – protein kinases 
C and A, and Ca2+/calmodulin-dependent protein kinases). Here, we observed a down-regulation of 
Prkcb (protein kinase C beta) and an up-regulation of Prkcd (protein kinase C delta). These findings 
are in accordance with the observed cerebral under-expression of IGF2 (insulin like growth factor 2) 
and over-expression of tumor necrosis factor (TNF), potential specific regulators of each protein 
kinase, respectively [46; 47].  
Finally, in order to further understand the potential role of POMC-derived cleavage peptides in pain 
alleviation, it is of prime importance to quote a study that assessed the role of β-endorphin in pain 
control [48]. When exposed to UV radiation, mice produce the POMC-derived peptide, β-endorphin, 
which in turn increases pain-related thresholds. It is therefore conceivable that the reported pain relief 
is a consequence of an increased production of vitamin D, collateral advantage of UV exposure. 
 
A tissue-specific reaction to painful stimuli 
If we exclude the three genes coding for opioids, 11 and 5 cerebral transcripts are associated with 
nociception and allodynia, respectively. In most cases, their up- or down-regulation is in accordance 
with their reported effect. Inhibition of Cx3cl1 [49], knockout of Adora2a [50; 41] and Tac1 genes 
[51] increase the threshold of mechanical and/or thermal nociception, while central administration of 
oxytocin enhances analgesia [52] and activation of orexin A (product of Hcrt) reduces hot plate 
nociceptive responses [53]. Contrariwise, knockout of Tph1 (tryptophane hydroxylase 1) decreases the 
threshold of thermal nociception [54] and Aloxe3 (arachidonate lipoxygenase 3) expression is 
increased in peripheral inflammation [55]. Aquaporin 1, alpha-2 adrenoreceptors (Adra2c) and 
histidine decarboxylase (Hdc) are also associated with nociception but their over-expression should not 
induce hypo-nociception [56-58]. In contrast, up- and down-regulation of Aloxe3, Gal and Tgfb1 do 
not fit with previous reports [59; 55; 60]. 
In recent years, vitamin D has been described as a cell-, tissue-, time-, individual-, dose-, pathology- 
and gender-dependent neurosteroid [3; 1]. Here, discrepancies observed with the transcriptomic study 
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are exclusively correlated with the variety of examined tissues. The differences are far from trivial 
since not a single allodynia-associated dysregulated gene in the cerebrum is detected in the spinal cord 
and vice versa. Once again, some observations are in accordance with published data. Knockout of 
Ptgs2 and Prx increasing allodynia [61; 62], it can be expected that an overexpression of these genes 
would lead to reduced allodynia. Conversely, a putative anti-allodynic effect of over-expressed Il6, 
Lepr and Thbs4 is more difficult to comprehend since interference of active interleukin 6 and 
thrombospondin 4 (TSP-4, product of Thbs4) and knockout of Lepr and Thbs4 decrease allodynia [63-
65].  
The nociception-associated transcriptomic profile in the DRG is also radically different from that 
observed in the cerebrum. Only one gene (Cx3cl1) out of 17 is commonly dysregulated in DRG and 
the cerebrum, although in an inverted way. Here again, alleviated pain could result from the over- or 
under-expression of most of the dysregulated genes. For example, it has been observed that knockouts 
of Cdk5r1, Trpm8 increase [66; 67] and knockout of Gnao1 decreases the threshold of thermal 
nociception [68], three findings in accordance with their respective under- and over-expression in the 
DRG. Neural cell adhesion molecule (NCAM) signaling mediates the analgesic effect of GDNF which 
we found overexpressed in the cerebrum [69], NOGO-66 (product of Rtn4) reduces neuropathic pain 
after sciatic nerve transection [70] and NGF is involved in the sensory perception of pain [71].  
 
New clues on vitamin D3-related molecular mechanisms in the nervous system 
Studies have shown that the VDR is very poorly expressed in the central nervous system [72; 73; 2] 
and only a restricted number of cerebral genes contain an upstream VDRE (Vitamin D response 
element) [74]. In conformity with these previous findings, the current study indicates that, at most, the 
expression of three nociception- and cholecalciferol-related genes is regulated by the VDR. And, out 
of three, only one (Ngf) displays a VDRE [74]. 
The current transcriptomic study provides new clues on potential and/or established intermediate 
regulators. Instead of up- or down-regulating gene transcription via a VDR/VDRE mechanism, 
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calcitriol may trigger activation or inhibition of some key proteins. This first row of regulators 
(MAP2K 1/2, ERK 1/2 (i.e. MAPK3/1), SRC, PTH, SMAD3) activates or inhibits a second row of 
proteins which, in turn, modulates the expression of the final effectors. This is in line with results from 
other studies done in human hepatocytes [75], chondrocytes, [76-78], keratinocytes and colonocytes 
[79]. Our study also suggests that calcidiol may not be as "inactive" as it is supposed to be, and does 
not need to be further hydroxylated to be efficient. This is in accordance with a study in which 25-
hydroxycholesterol was shown to amplify inflammatory signaling by mediating the recruitment of the 
activator protein 1 (AP-1) components of Fos and Jun to the promoters of a subset of Toll-like 
receptor-responsive genes [80]. It should be noted that the metabolic pathway suggesting that 
cholecalciferol may be active as well should be analyzed with caution as the proposed scheme comes 
from publications in which [1,25-hydroxycholesterol] (calcitriol) is mislabeled as cholecalciferol.  
 
Recommendations for a clinical translation 
Since recent reviews and meta-analyses deliver a mixed message about the potential therapeutic 
benefit of vitamin D2 or D3 supplementation against acute and chronic pain, reliable randomized, 
placebo-controlled clinical trials with undisputed conclusions remain to be performed. Among the 
major pre-requisites, vitamin D and its time/mode of administration, as well as the patient’s geno-
/phenotype, should be taken into account. 
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Legends 
 
Fig.1 Time course of mechanical nociceptive thresholds measured from the hindpaw of rats injected 
with CFA (complete Freund’s adjuvant) (a) or its vehicle (b) in the knee joint at Day 0. Comparison is 
shown for rats fed with a normal or vitamin D3 (vitD3) deficient diet, or vitamin D3-supplemented 
through diet or by gavage. Comparisons between supplemented and unsupplemented groups are 
indicated by asterisks at each time point. (#) indicates statistical significance when comparing values, 
for each time point, between vehicle- and CFA-injected animals receiving a similar diet. Statistical 
significance was assessed with Bonferroni posthoc test, illustrated as follows: p < 0.01 (**) and p < 
0.001 (*** or ###). 
 
Fig.2 a. Time course of mechanical nociceptive thresholds (a1) and cold allodynia scores (a2) measured 
in sham-operated and cuffed rats, supplemented or not with vitamin D3 (vitD3). b. Time course of 
mechanical nociceptive thresholds of rats supplemented or not with vitamin D3, from day 0 (time of 
surgery). Statistical significance was assessed with Bonferroni posthoc test, illustrated as follows: p < 
0.05 (*), p < 0.01 (**) or p < 0.001 (***) for comparisons between control and vitamin D3-
supplemented groups, and p < 0.05 (#), p < 0.01 (##) or p < 0.001 (###) for comparisons between 
sham and cuffed animals receiving a similar diet, at each time point. 
 
Fig.3 Extensive transcript dysregulation in the cerebrum, spinal cord and dorsal root ganglia (DRG) of 
rats, 2 days after being fed during 4 weeks with a vitamin D3-supplemented diet. a. Venn diagram 
showing the number of dysregulated genes in each tissue. The number of genes specifically 
dysregulated in DRG is more than twice as large as in other tissues. b. Venn diagram indicating the top 
canonical pathway in each tissue (dend. cell maturation: dendritic cell maturation; ILK: integrin linked 
kinase). c. Schematic overview of the genes associated with nociception in the cerebrum and DRG. d. 
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Schematic overview of the genes associated with allodynia in the cerebrum and spinal cord. Fold 
change cut off used for above analyses was -1.5 > FC > 1.5. 
 
Fig.4 Schematic opioid signaling pathway. Cerebral dysregulated genes, associated with opioid 
signaling, are highlighted (up: red; down: green) in a simplified view of the canonical pathway 
developed by Ingenuity©. 
 
Fig.5 RT-qPCR validation of several dysregulated transcripts in the dorsal root ganglia (DRG) (top 
graphs) and cerebrum (bottom graphs) of animals that received sham or cuff surgery with or without 
vitamin D3 supplementation. The different graphs illustrate the relative gene transcript expression for 
pro- and pre-pro-opioidergic peptides (POMC: pro-opio-melanocortin; PDYN: prodynorphin; PENK: 
proenkephalin) as well as for the three main opioid receptors (DOR: delta opioid receptor; KOR: 
kappa opioid receptor; MOR: mu opioid receptor). Statistical code for Sidak’s multiple comparisons 
test: ** p < 0.01; *** p < 0.001. 
 
Fig.6 Schematic view of the putative mechanisms of vitamin D3 action in the cerebrum. 
Cholecalciferol, 25-hydroxycholesterol (calcidiol) and calcitriol are associated with 9, 8 and 24 
nociception-, allodynia- and opiod- associated dysregulated genes, respectively. Five genes - Ctnnb1, 
Fos, Myc, Pomc, Th – are commonly regulated by the three metabolites. Each molecule regulates gene 
transcription in a specific manner. Regulators are either activated (brown) or inhibited (blue); genes 
are either up- (red) or down-regulated (green). 
 
Supplementary Fig.1 RT-qPCR validation of several dysregulated transcripts in the dorsal root 
ganglia (DRG) and cerebrum of animals that received sham or cuff surgery with or without vitamin D3 
supplementation. Relative expression of transcripts coding for diverse neurotransmitters, 
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neuropeptides and neurotrophic factors. Statistical code for Sidak’s multiple comparisons test: *** 
p < 0.001. 
 
Supplementary Fig.2 RT-qPCR validation of several dysregulated transcripts in the dorsal root 
ganglia (DRG) and cerebrum of animals that received sham or cuff surgery with or without vitamin D3 
supplementation. Relative expression of transcripts coding for proteins of the extracellular matrix and 
some chemokines. Statistical code for Sidak’s multiple comparisons test: *** p < 0.001. 
 
Supplementary Fig.3 Schematic view of the putative mechanisms of cholecalciferol action in the 
cerebrum (a), dorsal root ganglia (DRG) (b) and spinal cord (c). Five common regulators – Erk1/2 (i.e. 
Mapk3/1), Jnk (i.e. Mapk8), P38mapk, Prkca, Smad – are identified, although dysregulated genes 
differ greatly from one tissue to another. Regulators are either activated (brown) or inhibited (blue); 
genes are either up- (red) or down-regulated (green). 
 
Supplementary table 1 List of primer sequences used to amplify genes of interest by RT-qPCR. 
 
Supplementary table 2 Alphabetical list of over- (in red) and under-expressed genes (in green) in the 
dorsal root ganglia (DRG; yellow boxes), the spinal cord (blue boxes) and the cerebrum (green boxes) 
of cuff-operated rats supplemented with vitamin D3 compared with unsupplemented animals. 
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